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this association. ntroduction 
moking is one of the leading causes of premature 
eath ( World Health Organization, 2015 ). The majority of
dult smokers (80–90%) initiate smoking during adolescence 
 Wittchen et al., 2008 ) and genetic factors were found to
xplain 44% of the individual differences ( Vink et al., 2005 ).
dolescence is thus associated with an increased risk of de-
eloping long-lasting dependencies to nicotine and other 
ubstances ( Van De Ven et al., 2010 ), rendering this de-
elopmental period critical for the investigation of genetic 
isk factors and the resulting neurobehavioral mechanisms 
mplicated in tobacco smoking. However, our knowledge 
n how genes inﬂuence brain mechanisms in smoking is 
imited, and existing ﬁndings are often based on sample 
izes not large enough to yield conclusive results ( Munafo
nd Flint, 2011 ). Moreover, the investigation of smoking in 
dolescents is often hampered by reporting biases result- 
ng from self-report measures ( Kandel et al., 2006 ), thus
equiring complementation by biologically-veriﬁed mark- 
rs of nicotine use such as cotinine ( Keskitalo et al.,
009 ). 
Smoking in adolescence, in particular smoking initiation, 
s inﬂuenced by behaviours such as risk taking and impul-
iveness, which reﬂect dissociation between the develop- 
ent of the subcortical reward system and a comparatively 
elayed maturation of cortical inhibitory functions charac- 
eristic for this developmental period ( Lydon et al., 2014 ).
n adult smokers this maturation is complete, together with 
he direct consequence of chronic tobacco exposure, result- 
ng in a neurobehavioral context distinct from that in ado-
escents. This suggests that genetic factors and the biologi- 
al processes mediating smoking behaviour may be different 
n adolescents and adults. For example in adults, it has pre-
iously shown that a gene-cluster containing the dopamine luster has been implicated in adult smoking. Here, we inves-
idual genes in the TTC12-ANKK1-DRD2 cluster in smoking and
associated reward processing in adolescence. A meta-analysis
and self-reported smoking behaviours was performed in four
 = 14,084). The minor G-allele of rs2236709, mapping TTC12 ,
ed smoking ( p = 5.0 × 10 −4 ) and higher plasma cotinine levels
was linked to an increased ventral-striatal blood-oxygen level-
ing reward anticipation (n = 1,263) and with higher DRD2 gene
 0.013), but not with TTC12 or ANKK gene expression. These
2-ANKK1-DRD2 gene-cluster in adolescent smoking behaviours,
ment of DRD2 in the early stages of addiction and support the
ter-individual differences in dopaminergic transmission medi- 
o smoking. 
 by Elsevier B.V. This is an open access article under the CC
ivecommons.org/licenses/by-nc-nd/4.0/ ) 
eceptor 2 ( DRD2 ), the ankyrin repeat and kinase domain
ontaining 1 ( ANKK1 ) and the tetratricopeptide repeat do-
ain 12 ( TTC12 ) genes, is associated with tobacco smok-
ng ( Ducci et al., 2011; Gelernter et al., 2006 ). Similar re-
ults were found in adolescents with associations stronger 
n adolescence than in mid-adulthood ( Ducci et al., 2011 ).
hile this observation supports the notion of shifting bi-
logical processes underlying tobacco smoking across the 
ife span, the mechanisms by which variations in this gene-
luster exert their biological effect on smoking behaviour 
nd smoking initiation in adolescents have not yet been
lucidated. 
TTC12, ANKK1 and DRD2 are located in close proximity
n chromosome 11 in a region of high linkage disequilib-
ium (LD). In addition to nicotine, the gene-cluster has been
mplicated in alcohol and opiate addiction ( Nelson et al.,
013; Xu et al., 2004; Yang et al., 2007 ), suggesting that
ts inﬂuence on smoking may be exerted through a mech-
nism which is not substance-speciﬁc. TTC12 encodes for 
he tetratricopeptide repeat domain 12 protein, which is 
mplicated in dopaminergic transmission and neurodevelop- 
ent ( Castelo-Branco and Arenas, 2006 ). ANKK1 is hypoth-
sized to encode a signalling protein which mediates the
xpression of DRD2 ( Huang et al., 2009 ). DRD2 in turn has a
entral role in regulating the dopamine reward system that
ediates the reinforcing effects of all known addictive sub-
tances including nicotine mainly through striatal dopamin- 
rgic transmission ( Sweitzer et al., 2012 ). While other
opamine-related genes have been associated to smoking 
ehaviours ( Herman et al., 2014 ), we were interested in
urther investigating the role of this genetic region in early
moking initiation ( Mayhew et al., 2000 ) and in characteris-
ng the molecular and neurological mechanisms underlying 
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AIMS ANALYSIS RESULTS
Minor G allele of rs2336709 is associated with increased risk 
for smoking.
Higher plasma cotinine levels is strongly correlated with 
higher incidences of self-reported smoking.
Minor G allele of rs2336709 is associated with higher plasma 
cotinine levels.
Identify SNPs in TTC12-
ANKK1-DRD2 associated with 
adolescent smoking
Functionally characterise 
relevant SNPs
Assess the genotype effect 
on:
- Reward sensitivity (BOLD 
response in the ventral 
striatum during reward 
anticipation);
- Risk taking;
Minor G-allele of rs2236709 associated with increased 
expression of DRD2 in the striatum.
rs2236709-specific striatal DRD2-TTC12-ANKK1 expression in human 
post mortem striatum
GEO series GSE25219 database
Minor G-allele of rs2336709 associated with 
- higher BOLD response in the left ventral striatum.
- higher risk taking.
High risk taking associated with increased BOLD response in 
left ventral striatum.
Meta-analysis of self-reported smoking
NFBC-1966
N=4512
NFBC-1986
N=4307
ALSPAC
N=3674
IMAGEN
N=1591
Plasma cotinine level
ALSPAC
N=3674
Association between rs2336709 with BOLD response and risk taking. 
IMAGEN
N=1591
Fig. 1 Study aims, statistical analysis strategy, and results. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Speciﬁcally, we aimed (i) to identify single nucleotide
polymorphisms (SNPs) in the TTC12-ANKK1-DRD2 gene-
cluster, associated with self-reported cigarette smoking in
adolescents through meta-analysis of smoking data from
14,084 youths and blood cotinine levels, an objective mea-
sure of nicotine exposure, in a subset of 2,540 youths,
(ii) to functionally characterize relevant SNPs by measur-
ing allele-speciﬁc gene expression in human post-mortem
striatal brain tissue and (iii) to assess the genotype ef-
fect on reward sensitivity by analysing its relation with the
blood-oxygen level-dependent (BOLD) response in the ven-
tral striatum during reward anticipation, risk taking and to-
bacco smoking in a subset of adolescents from the IMAGEN
sample ( Fig. 1 ). 
Experimental procedures 
Participants 
We included 4512 adolescents from the Northern Fin-
land Birth Cohort NFBC1966 ( Sabatti et al., 2009 ), 4307
from NFBC1986 ( Vaarasmaki et al., 2009 ), 3674 from the
Avon Longitudinal Study of Parents and Children (ALSPAC)
( Golding, 1990 ), and 1591 (of which 1263 had data on func-
tional Magnetic Resonance Imaging (fMRI) data and 1085 on
risk taking) from IMAGEN ( Schumann et al., 2010 ). Demo-
graphic characteristics and phenotypic distribution of the
samples are reported in Table 1 . 
Smoking-related phenotypes 
Lifetime smoking, measuring the number and occasions
of cigarette smoking adapted for adolescents who have
lesser degree of exposure to smoke than adults, was self-
reported in each cohort (see Supplementary-Material for details in each cohort; Ducci et al., 2011 ), and recoded
into four categories: Never-Tried (never smoked), Ever-
Tried (smoked at least once), Smokers (smoked more than
once in the last 30 days), as previously used ( Ducci et
al., 2011 ) and Weekly-Smokers (smoked at least once a
week in the last month). We used Never-Tried as our ref-
erence group to contrast with Ever-Tried, and subsequently
validated our results by further contrasting with ado-
lescents who smoke occasionally ( Smokers ) and regularly
( Weekly-Smokers ). 
Genetic data 
We chose 33 SNPs based on data availability in the cohort
that was genotyped ﬁrst, i.e. NFBC1966. Not all of these 33
SNPs were available in each sample. (SNPs and LD structures
for each sample can be found in Supplementary-Fig. 1, MAF
of the separated cohorts can be found in Supplementary
Table 1). 
Cotinine level 
Plasma cotinine and genotypic data were available in
n = 2540 ALSPAC participants (see Supplementary-Material).
Brain genotype and gene expression 
We extracted gene expression levels of TTC12, ANKK1
and DRD2 in the striatum from the GEO series GSE25219
database ( Kang et al., 2011 ). Probe clusters assessing ex-
pression across the entire transcript of TTC12, ANKK1
and DRD2 were extracted (Transcript Cluster IDs 3349453,
3349535 and 3391653, respectively). We independently
replicated the association between DRD2 expression levels
A neurobiological pathway to smoking in adolescence 1107 
Table 1 Demographic characteristics and phenotypic distribution of the study samples. 
NFBC1966 NFBC1986 ALSPAC IMAGEN 
Whole sample fMRI sample Risk-taking sample 
Total ( N ) 4512 4307 3674 1591 1263 1085 
Male (in %) 47.3 47.6 51 49.6 48.9 48.9 
Age in years 14 16 15 14 14 14 
Country Finland Finland U.K Germany, U.K., 
France, Ireland 
Germany, U.K., 
France, Ireland 
Germany, U.K., 
France, Ireland 
Year of assessment 1980 2002 2006 2008 2008 2008 
Never-Tried 
n 1436 1539 1935 1139 914 771 
% 31.83 35.73 52.67 71.59 72.40 71.10 
Ever-Tried 
n 3076 2768 1739 452 349 314 
% 68.17 64.26 47.33 28.41 27.60 28.90 
Smokers 
n 757 982 891 189 146 133 
% 16.78 22.8 24.25 11.88 11.40 12.30 
Weekly-smokers 
n 309 844 371 100 71 65 
% 6.85 19.60 10.10 6.29 5.60 6.00 
Notes : The total sample size N was decomposed into participants, who never tried smoking ( Never-Tried ) as contrasted to those who have 
tried smoking at least once ( Ever-Tried ); this comparison is mutually exclusive. Out of those Ever-Tried participants, smokers and weekly 
smokers were taken; percentages refer to the total sample size ( N ). 
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ATranscript exon probe ID 3391671) and rs2236709 genotypes 
n 93 post-mortem cortical brain tissue samples of European 
thnicity, SNPExpress ( Heinzen et al., 2008 ). 
unctional MRI 
rain activation during reward anticipation was measured 
sing a modiﬁed monetary incentive delay (MID) fMRI task 
 Knutson et al., 2000 ) in a sample of 1263 individuals from
he IMAGEN sample. Gender, recruitment site and handed- 
ess were included as covariates. Based on previous ﬁndings 
 Yacubian et al., 2006 ), we focused on the ventral striatum
bilateral) as regions of interest (ROIs) (family-wise-error 
FWE)-corrected, p < 0.05) as 9-mm spheres from the con- 
rast ‘anticipation of large reward > anticipation of no re-
ard’ ( ± 15, 9, −9 in Montreal Neurological Institute (MNI)
pace) (see Supplementary-Materials for more details). 
isk taking 
e used the Cambridge Gambling Task (CGT) from 
he Cambridge Cognition Neuropsychological Test Auto- 
ated Battery (CANTAB; Cambridge Cognition http://www. 
ambridgecognition.com/ ). 
tatistical analyses 
enetic-association analyses and meta-analysis 
enetic data analysis used Plink v1.07 ( http://pngu.mgh. 
arvard.edu/ ∼purcell/plink/ ) if not otherwise indicated. ingle marker association analyses were conducted using 
ogistic or linear regression (for binary or quantitative 
raits, respectively) (see also Supplementary-Materials). 
ach genotype was coded as the number of copies of the
inor allele in all cohorts. Analyses controlled for gender,
all samples) age and site (IMAGEN). 
Meta-analysis was performed using the meta-analysis 
rocedure from Plink. Signiﬁcant results after Bonferroni- 
orrection were investigated further (see also Table 2 ). 
ssociation of genotype and BOLD responses in the 
entral striatum, brain activation and risk taking in the 
MAGEN cohort 
e carried forward the results of the conﬁrmatory analy-
is to investigate associations with brain activation and be-
avioural phenotypes underlying reward processing. ANOVAs 
omparing extracted mean ventral striatum BOLD responses 
cross genotypes for those SNPs showing associations to self-
eported smoking and cotinine were carried out in SPSS ver-
ion 20.0 (IBM Corp., Armonk, NY). We explored associa- 
ions of the smoking risk variants within TTC12-ANKK1-DRD2
ene-cluster with risk taking. We expected to ﬁnd positive
ssociations between genetic risk for smoking and risk tak-
ng and tested for this association one-tailed. 
esults 
 summary of the main ﬁndings is illustrated in Fig. 1 . 
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Table 2 Association between SNPs spanning the TTC12-ANKK1-DRD2 gene-cluster and smoking for Ever-Tried vs Never-Tried . 
BP Gene SNP Location MAF Ref allele/ N P OR Q I 2 
Other allele Samples Individuals (FEM) (REM) (FEM) (REM) 
112685412 TTC12 rs4517559 Flanking 
5 ′ UTR 
0.3736 C/T 4 13553 0.002 1.08 0.27 23.84 
112691986 TTC12 rs2236709 Intron 0.2588 G/A 4 14081 0.0005 ∗ 1.1 0.66 0 
112693407 TTC12 rs7927508 Intron 0.3667 G/A 3 9762 0.009 1.08 0.15 46.93 
112694133 TTC12 rs2156486 Intron 0.1814 G/T 4 13555 0.008 0.92 0.83 0 
112699378 TTC12 rs723077 Coding, 
Met73Leu 
0.4894 C/A 3 9771 0.06 0.94 0.63 0 
112704356 TTC12 rs10502172 Intron 0.4596 T/C 4 13675 0.004 0.93 0.16 41.71 
112705919 TTC12 rs2303380 Intron 
splice site 
0.3819 G/A 3 9771 0.49 1.02 0.18 41.76 
112716539 TTC12 rs2288159 Intron 0.1561 T/G 3 9768 0.13 1.06 0.63 0 
112721133 TTC12 rs4987094 Intron 0.1004 A/G 3 9777 0.12 1.07 0.67 0 
112735810 TTC12 rs2276070 Intron 0.1541 T/C 3 9774 0.13 1.06 0.65 0 
112739889 TTC12 rs719802 Intron 0.3953 T/C 3 9772 0.36 1.03 0.33 8.76 
112739985 TTC12 rs719804 Intron 0.249 G/A 3 9759 0.06 1.07 0.76 0 
112749387 TTC12 rs2282511 Flanking 
3 ′ UTR 
0.3455 A/C 3 11764 0.11 1.08 0.09 57.82 
112754346 TTC12 rs754672 Flanking 
3 ′ UTR 
0.4894 T/C 4 13552 0.002 0.92 0.48 0 
112761718 ANKK1 rs877138 Flanking 
5 ′ UTR 
0.3431 G/A 3 9777 0.25 1.04 0.37 0 
112768580 ANKK1 rs4590907 Intron 0.1436 G/T 4 13577 0.23 1.04 0.76 0 
112772031 ANKK1 rs7118900 Coding, 
Ala239Thr 
0.1896 A/G 3 9767 0.24 0.95 0.88 0 
112775225 ANKK1 rs4938016 Coding, 
Gly442Arg 
0.4452 G/C 3 11966 0.002 1.09 0.5 0 
112775370 ANKK1 rs2734849 Coding, 
His490Arg 
0.4886 G/A 4 13580 0.01 0.94 0.3 18.9 
112776038 ANKK1 rs1800497 Coding, 
Glu713Lys, 
TaqIA 
0.2026 A/G 4 13549 0.47 0.98 0.71 0 
112788669 DRD2 rs6277 Coding, 
Pro219Pro 
0.12201 A/G 3 11981 0.004 0.92 0.57 0 
112801119 DRD2 rs1076563 Intron 0.4127 C/A 3 9773 0.07 0.95 0.78 0 
112803549 DRD2 rs2471857 Intron 0.1577 T/C 3 9772 0.38 0.96 0.7 0 
112815891 DRD2 rs7125415 Intron 0.09914 T/C 3 9775 0.09 1.08 0.43 0 
112818599 DRD2 rs4648318 Intron 0.2538 C/T 3 9768 0.02 1.08 0.53 0 
112824662 DRD2 rs4274224 Intron 0.4823 G/A 3 9771 0.48 1.02 0.42 0 
112829684 DRD2 rs4581480 Intron 0.09919 C/T 3 9768 0.42 1.04 0.28 20.71 
112834984 DRD2 rs7131056 Intron 0.4205 C/A 3 9762 0.14 1.05 0.37 0 
112846601 DRD2 rs4938019 Intron 0.1447 C/T 4 13588 0.29 1.04 0.41 0 
112852165 DRD2 rs12364283 Flanking 
5 ′ UTR 
0.07563 G/A 3 9765 0.94 0.1 0.98 0 
112857971 DRD2 rs10891556 Intergenic 0.1758 T/G 3 9772 0.51 1.03 0.35 5.8 
112860946 DRD2 rs6589377 Intergenic 0.3776 G/A 4 13581 0.66 1.01 0.34 10.46 
112863421 DRD2 rs4482060 Intergenic 0.30032 T/A 3 11955 0.39 1.03 0.48 0 
Notes : Association between SNPs spanning the TTC12-ANKK1-DRD2 gene-cluster and self-reported smoking behaviour. Ever-Tried ( N = 8722) 
are compared to Never-Tried ( N = 6049) (binary logistic regression). Results from NFBC1966, ALSPAC, NFBC1986 and IMAGEN have been 
combined using meta-analysis. FEM = Fixed effect model, REM = Random effect model, Q = Cochrane’s Q statistic, I 2 = heterogeneity index 
(0–100), N = number of study samples. Signiﬁcant p values are in bold, of these those that remain signiﬁcant after Bonferroni correction for 
multiple testing are indicated by an asterisk. Thick lines indicate boundary between Linkage Disequilibrium blocks. 
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Fig. 2 Association between 33 single nucleotide polymorphisms (SNPs) covering the chromosome 11q23 TTC12-ANKK1-DRD2 gene- 
cluster and self-reported smoking behavior in adolescence. Results of the meta-analyses across the NFBC1966, NFBC1986, ALSPAC 
and IMAGEN cohorts are reported. p -values were meta- p -values computed under ﬁxed effect models. Given the multiple testing 
correction for all SNPs a signiﬁcance threshold of 0.0015 was used. The blue diamond indicates the most signiﬁcantly associated 
SNP. This was rs2236709 with p = 5.0 × 10 −4 for Ever-Tried vs. Never-Tried , rs2236709 with p = 0.001 for Smokers vs. Never-Tried 
and rs2236709 with p = 0.001 for Weekly Smokers vs. Never-Tried . For other SNPs, diamonds are colored in a white-to-red scale 
corresponding to R 2 values from 0 to 1 with the most signiﬁcant SNPs. The SNP position refers to National Center for Biotechnology 
Information build 35. Estimated recombination rates are from HapMap and gene annotations are from UCSC genome browser with 
build. (B) Forest plots for rs2236709 for the comparisons of the reference group (i.e. Never-Tried ) with Ever-Tried, Smokers and 
Weekly-Smokers . Box areas are proportional to the weight of the individual study. The overall summary odds ratios (OR) computed 
with a ﬁxed effect model are represented by a diamond whose width indicate the 95% conﬁdence interval (CI). Results of the anal- 
yses were as follows: Ever-Tried vs. Never-Tried OR = 1.10, 95%CI 1.04–1.16, p = 0.5.0 × 10 −4 ; Smokers vs. Never-Tried OR = 1.13, 
95% CI 1.05–1.22, p = 0.001 and Weekly-Smokers vs. Never-Tried OR = 1.16, 95% CI 1.06–1.27, p = 0.001 on the left, middle and right 
forest plots, respectively. (C, left plot) Association between 33 SNPs and cotinine level in the ALSPAC cohort. Blue diamond indicates 
the most signiﬁcantly associated SNP (rs2236709), as determined by linear regression analyses. Other diamonds are color-coded in 
a white-to-orange scale corresponding to increasing R 2 values of the respective SNP with rs2236709. The SNP position refers to 
National Center for Biotechnology Information build 35. Estimated recombination rates are from HapMap and gene annotations are 
from UCSC genome browser with build 35 coordinates. (C, right plot) Mean cotinine level (SE) according to rs2236709 genotypes 
(linear regression analysis: β = 0.11, p = 0.5.0 × 10 −4 ). Mean AA = 6.35, SE = 0.72, n = 1489; Mean AG = 7.94, SE = 1.18, n = 900; and 
Mean GG = 19.62, SE = 4.86, n = 151; post-hoc comparisons: AA vs. AG, p = 0.843, R 2 = 0.0005, AA vs. GG, p = 3.67E-5, R 2 = 0.02 and 
AG vs. GG, p = 0.001, R 2 = 0.013. 
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s  
O  eta-analysis exploring the association between 
TC12-ANKKI-DRD2 and smoking 
omparing adolescents who Never-Tried smoking with those 
ho Ever-Tried across four cohorts , we identiﬁed a signif- 
cant association with rs2236709 (Risk allele G; Odds ra- io (OR) = 1.10, 95% conﬁdence interval (CI): 1.04–1.16,
 = 5.0 × 10 −4 ) ( Fig. 2 and Table 2 ). The minor G-allele of
s2236709 was linked to increased risk for smoking amongst
ubgroups of regular smokers ( Smokers vs. Never-Tried :
R = 1.13, 95% CI: 1.05–1.22, p = 0.001; Weekly-Smokers
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Fig. 3 (A) Expression of DRD2, TTC12 and ANKK1 in the human striatum across the lifetime. The x -axis represents different stages 
of fetal and postnatal development, as indicated. PCW = post-conception weeks, M = months, Y = years. (B) Striatal expression of 
DRD2 corrected for effects of developmental stage and stratiﬁed by rs2236709 genotypes. The dotted line visualizes the linear 
regression against the number of minor G-alleles ( n AA = 22, n AG = 16 and, n GG = 5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 vs. Never-Tried : OR = 1.16, 95% CI: 1.06–1.27, p = 0.001)
( Fig. 2 B; Supplementary-Material Tables 2 and 3). 
Association of cotinine level and self-reported 
smoking behavior 
Higher cotinine levels correlated with a higher num-
ber of self-reported cigarettes (Spearman’s ρ = 0.33,
p = 3.7 × 10 −53 ), thus validating self-reported smoking.
Mean cotinine levels in ng/ml (SD) for each cate-
gory of smokers were: Never-Tried = 0.73 (2.73), Ever-
Tried = 15.18 (46.51), Smokers = 28.13 (61.64) and Weekly-
Smokers = 64.97 (82.51). One-way ANOVA revealed sig-
niﬁcant difference across lifetime smoking categories
(F(3,3319) = 25.09, p = 4.80 × 10 −16 , R 2 = 0.022). Stratiﬁca-
tion of mean plasma cotinine levels according to rs2236709
genotypes indicated a signiﬁcant positive association
with the minor G-allele [F(2,2537) = 9.64, p = 6.76 × 10 −5 ,
R 2 = 0.003) ( Fig. 2 C, Supplementary Table 4), thus conﬁrm-
ing the association of rs2236709 with self-reported smoking.
Rs2236709 inﬂuences on striatal DRD2 expression 
Rs2236709 is located within TTC12 and is in LD with
the other genes in the locus, ANKK1 and DRD2 (see
Supplementary-Material Fig. 1). To investigate which of
these three genes contributed to the effects of rs2236709
on smoking, we analysed their expression in post-mortem
human brain samples. Fig. 3 A shows expression of TTC12,
ANKK1 and DRD2 in the striatum across the lifetime. It was
indicated that DRD2 mRNA levels in the striatum increased  steadily during the foetal stages and reached a peak in ado-
lescence, while ANKK1 and TTC12 expression levels were
low overall. We performed association analyses to investi-
gate the effects of rs2236709 on striatal DRD2, TTC12 and
ANKK1 expression and included developmental stage as a
covariate. The minor G-allele of rs2236709 was associated
with increased expression of DRD2 in the striatum ( r = 0.39,
p = 0.013, df = 37; Fig. 3 B). Neither expression of TTC12
nor that of ANKK1 was inﬂuenced by rs2236709 genotypes
( p = 0.176 and p = 0.244, respectively). There was no as-
sociation of gender ( p = 0.627) or RNA integrity ( p = 0.296)
with DRD2 gene expression. 
As there is, to our knowledge, no other dataset contains
expression levels of DRD2 in the striatum and rs2236709
genotype data, we independently replicated the associa-
tion between DRD2 expression levels and rs2236709 in cor-
tical brain tissue samples of European ethnicity ( Heinzen
et al., 2008 ), and found the association to be signiﬁcant
( p uncorrected = 0.003, p corrected = 0.049, corrected for the num-
ber of DRD2 probes). 
Association of rs2236709 genotype and ventral 
striatum BOLD response during reward anticipation
As our results suggest that altered dopaminergic trans-
mission in reward-related brain areas (e.g., the ventral
striatum) may underlie the association of rs2236709 with
smoking, we further measured associations of this vari-
ant with BOLD response during reward anticipation in
the ventral striatum of 1236 IMAGEN participants. Due
to a skewed allele distribution of rs2236709 ( n AA = 706,
n AG = 467, n GG = 90), we pooled heterozygotes and GG-
homozygotes (G-carriers) and compared them to AA-
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lomozygotes. Our results show a signiﬁcantly higher 
OLD response in the left ventral striatum of G-carriers 
s. AA-homozygotes [F(1,1261) = 5.803, p uncorrected = 0.016, 
 corrected = 0.032, R 2 = 0.005, Supplementary-Materials), in- 
icating an association of the risk allele (G) with greater
eward sensitivity and increased DRD2 expression. No sig- 
iﬁcant associations of rs2236709 genotypes with BOLD re- 
ponse in the right ventral striatum ( p = 0.237) were ob-
erved. 
ssociation between risk taking, rs2236709, and 
entral striatum BOLD response during reward 
nticipation 
s we expected a positive association between genetic risk 
or smoking and risk taking, this association was tested 
ne-tailed. Risk taking positively associated with risk al- 
ele (G) of rs2236709 ( r = 0.056, p = 0.033), and ventral
triatal BOLD response (left: r = 0.033, p = 0.112; right:
 = 0.049, p = 0.034). Risk taking also signiﬁcantly associ-
ted with the number of occasions of lifetime cigarette 
moking ( r = 0.056, p = 0.034). 
iscussion 
he current study carried out a neurobehavioral character- 
zation of the TTC12 - ANKK1 - DRD2 gene-cluster and smoking
n adolescence using four large datasets from different Eu- 
opean countries. Our result demonstrated that this gene- 
ocus exerts its effect on smoking behaviors such as smoking 
nitiation and frequency already in the very early stages of
icotine abuse. To attain a mechanistic understanding of the 
ssociations of the minor G-allele of rs2236709 with both 
ncreased self-reported nicotine intake and higher cotinine 
evels in adolescents, we found that the genetic risk factor
s2236709 regulates DRD2 gene expression, and is also asso- 
iated with activation of ventral striatum during reward an- 
icipation and risk taking, a behaviour associated with drug 
nitiation. 
DRD2 is a key molecular determinant of reward sensitivity 
 Sweitzer et al., 2012 ), which reaches its peak expression in
he striatum during adolescence. High DRD2 expression in- 
reases sensitivity to rewarding stimuli, thus increases sen- 
itivity to the effects of substances ( DiNieri et al., 2011 ) as
ell as risk taking ( Cocker et al., 2012 ). This combination
ncreases vulnerability for addictive behaviors ( Leyton and 
ezina, 2014 ). Thus, enhanced DRD2 expression in adoles- 
ents is likely to be one component of risk for substance
buse and smoking in particular. Whereas DRD2 receptor 
vailability is reduced during the compulsive stages of sub- 
tance addiction ( Johnson and Kenny, 2010 ), early substance 
se has been linked to increased DRD2 expression levels 
n the ventral striatum ( Koob and Volkow, 2009 ), suggest-
ng a differential regulation of DRD2 in adolescents exper- 
menting with drugs compared to established nicotine de- 
endence in adults. 
Our results suggest that carriers of rs2236709 G-risk allele 
re at a particularly high risk of nicotine abuse, presumably 
ue to an allele-speciﬁc increase in DRD2 expression, in car-
iers of the G-risk allele found in human post-mortem brainissue retrieved from the striatum. While our cohorts have
ifferent ancestry the LD structure of the rs2236709 locus 
s similar, suggesting that the ﬁndings in the post-mortem
uman brains can be extended to all our cohorts. Concur-
ently, increased ventro-striatal response during reward an- 
icipation was observed in carriers of the G-risk allele in
unctional neuroimaging analyses of 14 year-old IMAGEN 
articipants. Together these ﬁndings suggest an enhanced 
ventro-)striatal dopaminergic activity underlying the ob- 
erved association. Our cognitive ﬁndings using the IMAGEN 
ample are in keeping with this interpretation, namely that
arriers of the risk allele showed higher risk taking behavior,
hich in turn was associated with increased ventral striatal
ctivation and with increased nicotine use. 
We did not detect signiﬁcant association between smok- 
ng frequency and ventral striatal activity in this sam-
le of 14 year-old adolescents in which 72% had never
moked. This might be explained by insufﬁcient exposure 
o cigarettes due to young age and/or reduced availability
f cigarettes compared to older cohorts, such as NFBC1966
here only 32% adolescents had never smoked at that
ge. 
Rs2236709 is localized in the second intron of the TTC12
ene locus and tags a haplotype that ranges from the pro-
oter to the third exon of the TTC12 gene. While it is cor-
elated with DRD2 expression in the striatum, it is not as-
ociated with the expression of TTC12 itself. However, it is
ell known that even Cis -acting gene expression can be reg-
lated by genetic variations that are not immediately adja-
ent to the gene they are regulating ( Kirsten et al., 2015 ). 
This study has some limitations: (i) different cohorts ap-
lied different measures to assess smoking behaviour, which 
imited us from obtaining a continuous measure consistent 
cross studies, but instead combined information into dis- 
inct groups. (ii) Smoking habits have been subject to chang-
ng societal and legal attitudes over the last decades. Data
cquisition among the different cohorts spreads over sev- 
ral decades, which was not accounted for. (iii) Cotinine can
lso account for second hand smoking, moreover the half-
ife of cotinine being 16–18 h is much shorter than some of
he self-reported smoking behaviours that measure longer 
obacco use ( Jarvis et al., 1988; Perez-Stable et al., 1995;
artiainen et al., 2002 ). (iv) Genetic heterogeneity between
tudies should be noted as we pooled all samples of Euro-
ean ancestry due to limited data on adolescent smoking.
wo cohorts (NFBC1966, NFBC1986) were of Finnish ances- 
ry, and genetically distinct from the other two European
ohorts (IMAGEN, ALSPAC), which might limit generalization 
f our ﬁndings. Notably, despite some differences of the mi-
or allele frequency (MAF), the direction of the smoking-risk
NP effects is consistent across cohorts and I 2 of rs2236709
ndicated no heterogeneity across cohorts. 
Our work proposes a neurobiological pathway to nicotine 
buse in a developmental period characterized by both vul-
erability to the effects of nicotine, and great therapeu-
ic potential to prevent or overcome its abuse ( Toumbourou
t al., 2007 ). Noting the recent success of interventions
argeting behavioral risk proﬁles ( Conrod et al., 2013 ), our
eurobehavioral characterization provided a basis for devel- 
ping interventions targeting biological mechanisms under- 
ying nicotine abuse. 
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